Cargando…

Plasma cell free DNA methylation markers for hepatocellular carcinoma surveillance in patients with cirrhosis: a case control study

BACKGROUND: Hepatocellular carcinoma (HCC) is the leading cause of death in patients with cirrhosis, primarily due to failed early detection. HCC screening is recommended among individuals with cirrhosis using biannual abdominal ultrasound, for earlier tumor detection, administration of curative tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Lewin, Jörn, Kottwitz, Denise, Aoyama, Johanna, deVos, Theo, Garces, Jorge, Hasinger, Oliver, Kasielke, Stefanie, Knaust, Florian, Rathi, Preeti, Rausch, Sebastian, Weiss, Gunter, Zipprich, Alexander, Mena, Edward, Fong, Tse-Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7995734/
https://www.ncbi.nlm.nih.gov/pubmed/33765926
http://dx.doi.org/10.1186/s12876-021-01714-8
_version_ 1783669971464749056
author Lewin, Jörn
Kottwitz, Denise
Aoyama, Johanna
deVos, Theo
Garces, Jorge
Hasinger, Oliver
Kasielke, Stefanie
Knaust, Florian
Rathi, Preeti
Rausch, Sebastian
Weiss, Gunter
Zipprich, Alexander
Mena, Edward
Fong, Tse-Ling
author_facet Lewin, Jörn
Kottwitz, Denise
Aoyama, Johanna
deVos, Theo
Garces, Jorge
Hasinger, Oliver
Kasielke, Stefanie
Knaust, Florian
Rathi, Preeti
Rausch, Sebastian
Weiss, Gunter
Zipprich, Alexander
Mena, Edward
Fong, Tse-Ling
author_sort Lewin, Jörn
collection PubMed
description BACKGROUND: Hepatocellular carcinoma (HCC) is the leading cause of death in patients with cirrhosis, primarily due to failed early detection. HCC screening is recommended among individuals with cirrhosis using biannual abdominal ultrasound, for earlier tumor detection, administration of curative treatment, and improved survival. Surveillance by imaging with or without biomarkers such as alpha-fetoprotein (AFP) remains suboptimal for early stage HCC detection. Here we report on the development and assessment of methylation biomarkers from liquid biopsies for HCC surveillance in cirrhotic patients. METHODS: DNA methylation markers including the HCCBloodTest (Epigenomics AG) and a DNA-methylation panel established by next generation sequencing (NGS) were assessed using a training/testing design. The NGS panel algorithm was established in a training study (41 HCC patients; 46 cirrhotic non-HCC controls). For testing, plasma samples were obtained from cirrhotic patients (Child class A or B) with (60) or without (103) early stage HCC (BCLC stage 0, A, B). The assays were then tested using blinded sample sets and analyzed by preset algorithms. RESULTS: The HCCBloodTest and the NGS panel exhibited 76.7% and 57% sensitivities at 64.1% and 97% specificity, respectively. In a post-hoc analysis, a combination of the NGS panel with AFP (20 ng/mL) achieved 68% sensitivity at 97% specificity (AUC = 0.9). CONCLUSIONS: Methylation biomarkers in cell free plasma DNA provide a new alternative for HCC surveillance. Multiomic panels comprising DNA methylation markers with other biological markers, such as AFP, provide an option to further increase the overall clinical performance of surveillance via minimally invasive blood samples. Trial Registration: Test set study—ClinicalTrials.gov (NCT03804593) January 11, 2019, retrospectively registered. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12876-021-01714-8.
format Online
Article
Text
id pubmed-7995734
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-79957342021-03-30 Plasma cell free DNA methylation markers for hepatocellular carcinoma surveillance in patients with cirrhosis: a case control study Lewin, Jörn Kottwitz, Denise Aoyama, Johanna deVos, Theo Garces, Jorge Hasinger, Oliver Kasielke, Stefanie Knaust, Florian Rathi, Preeti Rausch, Sebastian Weiss, Gunter Zipprich, Alexander Mena, Edward Fong, Tse-Ling BMC Gastroenterol Research Article BACKGROUND: Hepatocellular carcinoma (HCC) is the leading cause of death in patients with cirrhosis, primarily due to failed early detection. HCC screening is recommended among individuals with cirrhosis using biannual abdominal ultrasound, for earlier tumor detection, administration of curative treatment, and improved survival. Surveillance by imaging with or without biomarkers such as alpha-fetoprotein (AFP) remains suboptimal for early stage HCC detection. Here we report on the development and assessment of methylation biomarkers from liquid biopsies for HCC surveillance in cirrhotic patients. METHODS: DNA methylation markers including the HCCBloodTest (Epigenomics AG) and a DNA-methylation panel established by next generation sequencing (NGS) were assessed using a training/testing design. The NGS panel algorithm was established in a training study (41 HCC patients; 46 cirrhotic non-HCC controls). For testing, plasma samples were obtained from cirrhotic patients (Child class A or B) with (60) or without (103) early stage HCC (BCLC stage 0, A, B). The assays were then tested using blinded sample sets and analyzed by preset algorithms. RESULTS: The HCCBloodTest and the NGS panel exhibited 76.7% and 57% sensitivities at 64.1% and 97% specificity, respectively. In a post-hoc analysis, a combination of the NGS panel with AFP (20 ng/mL) achieved 68% sensitivity at 97% specificity (AUC = 0.9). CONCLUSIONS: Methylation biomarkers in cell free plasma DNA provide a new alternative for HCC surveillance. Multiomic panels comprising DNA methylation markers with other biological markers, such as AFP, provide an option to further increase the overall clinical performance of surveillance via minimally invasive blood samples. Trial Registration: Test set study—ClinicalTrials.gov (NCT03804593) January 11, 2019, retrospectively registered. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12876-021-01714-8. BioMed Central 2021-03-25 /pmc/articles/PMC7995734/ /pubmed/33765926 http://dx.doi.org/10.1186/s12876-021-01714-8 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Lewin, Jörn
Kottwitz, Denise
Aoyama, Johanna
deVos, Theo
Garces, Jorge
Hasinger, Oliver
Kasielke, Stefanie
Knaust, Florian
Rathi, Preeti
Rausch, Sebastian
Weiss, Gunter
Zipprich, Alexander
Mena, Edward
Fong, Tse-Ling
Plasma cell free DNA methylation markers for hepatocellular carcinoma surveillance in patients with cirrhosis: a case control study
title Plasma cell free DNA methylation markers for hepatocellular carcinoma surveillance in patients with cirrhosis: a case control study
title_full Plasma cell free DNA methylation markers for hepatocellular carcinoma surveillance in patients with cirrhosis: a case control study
title_fullStr Plasma cell free DNA methylation markers for hepatocellular carcinoma surveillance in patients with cirrhosis: a case control study
title_full_unstemmed Plasma cell free DNA methylation markers for hepatocellular carcinoma surveillance in patients with cirrhosis: a case control study
title_short Plasma cell free DNA methylation markers for hepatocellular carcinoma surveillance in patients with cirrhosis: a case control study
title_sort plasma cell free dna methylation markers for hepatocellular carcinoma surveillance in patients with cirrhosis: a case control study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7995734/
https://www.ncbi.nlm.nih.gov/pubmed/33765926
http://dx.doi.org/10.1186/s12876-021-01714-8
work_keys_str_mv AT lewinjorn plasmacellfreednamethylationmarkersforhepatocellularcarcinomasurveillanceinpatientswithcirrhosisacasecontrolstudy
AT kottwitzdenise plasmacellfreednamethylationmarkersforhepatocellularcarcinomasurveillanceinpatientswithcirrhosisacasecontrolstudy
AT aoyamajohanna plasmacellfreednamethylationmarkersforhepatocellularcarcinomasurveillanceinpatientswithcirrhosisacasecontrolstudy
AT devostheo plasmacellfreednamethylationmarkersforhepatocellularcarcinomasurveillanceinpatientswithcirrhosisacasecontrolstudy
AT garcesjorge plasmacellfreednamethylationmarkersforhepatocellularcarcinomasurveillanceinpatientswithcirrhosisacasecontrolstudy
AT hasingeroliver plasmacellfreednamethylationmarkersforhepatocellularcarcinomasurveillanceinpatientswithcirrhosisacasecontrolstudy
AT kasielkestefanie plasmacellfreednamethylationmarkersforhepatocellularcarcinomasurveillanceinpatientswithcirrhosisacasecontrolstudy
AT knaustflorian plasmacellfreednamethylationmarkersforhepatocellularcarcinomasurveillanceinpatientswithcirrhosisacasecontrolstudy
AT rathipreeti plasmacellfreednamethylationmarkersforhepatocellularcarcinomasurveillanceinpatientswithcirrhosisacasecontrolstudy
AT rauschsebastian plasmacellfreednamethylationmarkersforhepatocellularcarcinomasurveillanceinpatientswithcirrhosisacasecontrolstudy
AT weissgunter plasmacellfreednamethylationmarkersforhepatocellularcarcinomasurveillanceinpatientswithcirrhosisacasecontrolstudy
AT zipprichalexander plasmacellfreednamethylationmarkersforhepatocellularcarcinomasurveillanceinpatientswithcirrhosisacasecontrolstudy
AT menaedward plasmacellfreednamethylationmarkersforhepatocellularcarcinomasurveillanceinpatientswithcirrhosisacasecontrolstudy
AT fongtseling plasmacellfreednamethylationmarkersforhepatocellularcarcinomasurveillanceinpatientswithcirrhosisacasecontrolstudy